long-term oral chemotherapy agents in adjuvant (i.e. follow-up) cancer treatment represents new and exciting territory for Karmanos scientists. Capecitabine was the first FDA-approved oral chemotherapy treatment, gaining approval for human use in 1998. Since then, other oral cancer agents have been developed, including Tamoxifen for breast cancer patients and Methotrexate, which is used to treat breast, skin, head, neck and lung cancers.
"There are not many low-dose applications for oral chemotherapy," Dr. Yoo said. "Intravenous chemotherapy is still the norm. From the innovation stand-point, it's really a new way of looking at chemotherapy."
Karmanos' study is investigator-initiated in which researchers worked with capecitabine's manufacturer Roche to perform the study. Dr. Yoo said Karmanos continues to enroll patients in the Phase II study and hopes that down the road, the study will enter a third phase.
"We thought it was a good study, one that explores the effects of low-dose, long-term oral chemotherapy treatments," said Dr. Yoo. He added that not only does low-dose, long-term adjuvant therapy for HNSCC patients promise longer survival and lower recurrence of tumors, it's an easy treatment method, one with minimum side effects, and one that would ensure all patients could undergo adjuvant therapy.
Located in mid-town Detroit, MI, the Barbara Ann Karmanos Cancer Institute is one of 40 National Cancer Institute-designated comprehensive cancer centers in the United States. Caring for more than 6,000 new patients annually on a budget of $216 million, conducting more than 700 cancer-specific scientific investigation programs and clinical trials, the Karmanos Cancer Institute is among the nation's best cancer centers. Through the commitment of 1,000 staff, including nearly 300 faculty members, and supported by thousands of volunteer and financial donors, the Institute str
Page: 1 2 3 Related medicine technology :1
|SOURCE Barbara Ann Karmanos Cancer Institute|
Copyright©2009 PR Newswire.
All rights reserved
. Researchers Present Safety and Efficacy Results of 429 Patients Treated With Radiofrequency Ablation for Pre-Cancerous Barretts Esophagus2
. Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis3
. Tufts Medical Center Researchers Create a New Predictive Model for Age-related Macular Degeneration (AMD)4
. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia5
. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference6
. Researchers Discover Metabolite Linked to Aggressive Prostate Cancer7
. Why Wait for an Anti-Aging Drug? Researchers Interviewed on CBS-TVs 60 MINUTES Discover Longevinex(R) Nutriceutical Matrix Activates 9-Fold More Longevity Genes than Plain Resveratrol8
. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF9
. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay10
. Researchers at Axial Biotech Develop a DNA Test for Scoliosis11
. K-State Researchers Awarded Nearly $1 Million to Test Remedies, Investigate Link Between E. Coli and Distillers Grains